ACNU · Additional Condition for Nonprescription Use
A new era of switches.
Until now a medicine could only switch to nonprescription if the label alone could keep it safe. An ACNU adds FDA-approved software that decides if a medicine is appropriate and safe for the person buying it. Every switch the label couldn’t carry is back on the table.
Read the ACNU FAQThe ACNU Business Case
Own the Gate.
Brands pay to bring a patient to the door, then send them to a doctor, a PBM and a pharmacy counter they don’t own. Most of those prescriptions never become a patient on therapy. An ACNU keeps the decision, and the sale, on your site.
Read the Business CaseOf every 100 prescriptions written
- never picked up
- 28
- stopped within a year
- 36
- still taking it at 12 months
- 36
SourcesAMN Healthcare 2025 wait-time survey (31 days) · Fischer et al., J Gen Intern Med 2010 (28% never filled) · Vrijens et al., BMJ 2008 (about half stop within a year)
What is ACNU?
Democratizing Care through Convenience & Accessibility.
'/%3e%3c/svg%3e)
Consumers want convenient, accessible healthcare that fits their dynamic lifestyle.- ACNU is the FDA rule that opens a new class of Rx-to-OTC switches: medicines a label alone couldn’t carry can go nonprescription with tech-assisted screening.
- Our ACNU technology adheres to the SaMD standard and has proven to be 96% successful in clinical trials.
Success Story
TACTiC Trial ’24
In AstraZeneca’s Technology-Assisted Cholesterol Trial in Consumers (TACTiC), our device successfully demonstrated that participants could:
- Safely and effectively self-select, acquire, and use rosuvastatin calcium 5-mg over six months.
- Manage statins using technology-assisted self-management tools.
Measurable change
Six months, no practitioner
- Self-selection
- 91.7%
- Actual use
- 98.1%
- Adherence
- 95.0%
- LDL reduction
- −35.5%
The Journey
Your Partner through the ACNU Journey
From feasibility to commercialization, we optimize for program success. Three phases, one team, and a public grade to start from.
- Start here
ACNU Feasibility
- Is there sufficient unmet need?
- Is the safety profile acceptable?
- What is the potential market size?
- 6 to 8 weeks
Build & Study
- Self-selection technology.
- SaMD validation and cybersecurity.
- Clinical trial recruiting and support.
- 12 weeks to AUS
Commercialization
- Checkout and fulfillment.
- Reporting and optimization.
- Marketing and AI visibility.
Expedite Time-to-Market
Weeks from a go decision
Pre-studies
- 6 wks
- Label comprehension and self-selection studies on the built technology.
Validation studies
- 8 wks
- SaMD validation and cybersecurity, ready for review.
Actual use study
- 12 wks
- From go decision to an actual use study on our ACNU platform.
Strategy Guide
Facing a patent cliff?
Six ways brands defend revenue through loss of exclusivity, and the one that turns an expiring prescription into a subscription annuity: the nonprescription switch, now open to chronic-condition drugs under ACNU.
Read Drug Patent Cliff StrategiesIndustry estimates
$200B+
Annual U.S. branded revenue facing loss of exclusivity by 2030.
Connect With Us
Accelerate brand visibility and scale access to your treatments.
Whether the opportunity begins with visibility or nonprescription access, we’ll help you find the clearest next move across Search, AI and ACNU.
contact@idea-evolver.com